ScoreWhy is Santhera Pharmaceuticals Holding AG ?
1
Poor Management Efficiency with a low ROE of 15.77%
- The company has been able to generate a Return on Equity (avg) of 15.77% signifying low profitability per unit of shareholders funds
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -5.44% and Operating profit at -209.70% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 15.77% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -5.44% and Operating profit at -209.70% over the last 5 years
4
Negative results in Jun 25
- INTEREST(HY) At CHF 4.8 MM has Grown at 19.08%
- ROCE(HY) Lowest at -288.14%
- RAW MATERIAL COST(Y) Grown by 185.62% (YoY)
5
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 1.20%, its profits have fallen by -209.3%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Santhera Pharmaceuticals Holding AG for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Santhera Pharmaceuticals Holding AG
-100.0%
0.13
51.86%
Switzerland SMI
1.42%
-0.08
16.69%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-5.44%
EBIT Growth (5y)
-209.70%
EBIT to Interest (avg)
-1.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.41
Sales to Capital Employed (avg)
0.66
Tax Ratio
0.75%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.51%
ROE (avg)
15.77%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-57.51
EV to EBIT
-3.99
EV to EBITDA
-4.49
EV to Capital Employed
3.79
EV to Sales
4.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-95.06%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CHF 6.51 MM
NET SALES(Q)
At CHF 24.01 MM has Grown at 70.14%
DEBT-EQUITY RATIO
(HY)
Lowest at -2,259.27 %
-15What is not working for the Company
INTEREST(HY)
At CHF 4.8 MM has Grown at 19.08%
ROCE(HY)
Lowest at -288.14%
RAW MATERIAL COST(Y)
Grown by 185.62% (YoY
OPERATING PROFIT(Q)
Lowest at CHF -32.61 MM
PRE-TAX PROFIT(Q)
Lowest at CHF -42.81 MM
NET PROFIT(Q)
Lowest at CHF -42.88 MM
EPS(Q)
Lowest at CHF -3.04
Here's what is working for Santhera Pharmaceuticals Holding AG
Net Sales
At CHF 24.01 MM has Grown at 70.14%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (CHF MM)
Operating Cash Flow
Highest at CHF 6.51 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CHF MM)
Debt-Equity Ratio
Lowest at -2,259.27 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Santhera Pharmaceuticals Holding AG
Pre-Tax Profit
At CHF -42.81 MM has Fallen at -121.21%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (CHF MM)
Net Profit
At CHF -42.88 MM has Fallen at -119.63%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (CHF MM)
Interest
At CHF 4.8 MM has Grown at 19.08%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CHF MM)
Operating Profit
Lowest at CHF -32.61 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CHF MM)
Pre-Tax Profit
Lowest at CHF -42.81 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (CHF MM)
Net Profit
Lowest at CHF -42.88 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (CHF MM)
EPS
Lowest at CHF -3.04
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (CHF)
Raw Material Cost
Grown by 185.62% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
